Docosahexaenoic acid trials in cystic fibrosis: A review of the rationale behind the clinical trials
- 1 March 2005
- journal article
- review article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 4 (1) , 27-34
Abstract
No abstract availableThis publication has 78 references indexed in Scilit:
- Arachidonic Acid Regulates Surface Expression of Epithelial Sodium ChannelsJournal of Biological Chemistry, 2003
- Effect of an 8‐month treatment with omega‐3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosisJournal of Parenteral and Enteral Nutrition, 2003
- Anti-inflammatory effects of montelukast in mild cystic fibrosisAnnals of Allergy, Asthma & Immunology, 2002
- Omega‐3 fatty acids suppress the enhanced production of 5‐Iipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosisEuropean Journal of Clinical Investigation, 1995
- Effect of High-Dose Ibuprofen in Patients with Cystic FibrosisNew England Journal of Medicine, 1995
- Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjectsThe Journal of Pediatrics, 1994
- Effect of Administration of Gamma-Linolenic Acid on the Fatty Acid Composition of Serum Phospholipids and Cholesteryl Esters in Patients with Cystic FibrosisAnnals of Nutrition and Metabolism, 1994
- Effects of dietary purified eicosapentaenoic acid (20:5(n − 3)) and docosahexaenoic acid (22:6(n − 3)) on fatty acid desaturation and oxidation in isolated rat liver cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Increase of Long Chain Omega 3 Fatty Acids in the Major Serum Lipid Classes of Patients with Cystic FibrosisAnnals of Nutrition and Metabolism, 1992
- ABNORMAL LEVELS OF PROSTAGLANDINS AND FATTY ACIDS IN BLOOD OF CHILDREN WITH CYSTIC FIBROSISThe Lancet, 1978